MX2016012466A - Aptamero para el factor de crecimiento de fibroblastos 2 y uso del mismo. - Google Patents
Aptamero para el factor de crecimiento de fibroblastos 2 y uso del mismo.Info
- Publication number
- MX2016012466A MX2016012466A MX2016012466A MX2016012466A MX2016012466A MX 2016012466 A MX2016012466 A MX 2016012466A MX 2016012466 A MX2016012466 A MX 2016012466A MX 2016012466 A MX2016012466 A MX 2016012466A MX 2016012466 A MX2016012466 A MX 2016012466A
- Authority
- MX
- Mexico
- Prior art keywords
- aptamer
- fgf2
- substance
- inhibitory activity
- activity
- Prior art date
Links
- 108091023037 Aptamer Proteins 0.000 title abstract 5
- 101150019331 FGF2 gene Proteins 0.000 title 1
- YSFTYXKQUONNFY-NQXPEFQPSA-N fgf2 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 YSFTYXKQUONNFY-NQXPEFQPSA-N 0.000 title 1
- 239000000126 substance Substances 0.000 abstract 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 abstract 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000002372 labelling Methods 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
Abstract
La presente invención provee un aptámero que tiene una actividad inhibidora sobre el FGF2; un complejo que contiene un aptámero que tiene una actividad de unión o una actividad inhibidora sobre el FGF2, y una sustancia funcional (por ejemplo, sustancia de afinidad, sustancia de marcación, enzima, vehículo de suministro de fármacos o fármaco, y similares); un medicamento, reactivo de diagnóstico o agente de marcación que contiene un aptámero que tiene una actividad de unión o una actividad inhibidora sobre el FGF2, o un complejo que contiene dicho aptámero y una sustancia funcional; y similares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014060966 | 2014-03-24 | ||
PCT/JP2015/058992 WO2015147017A1 (ja) | 2014-03-24 | 2015-03-24 | Fgf2に対するアプタマー及びその使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016012466A true MX2016012466A (es) | 2017-01-06 |
Family
ID=54195529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016012466A MX2016012466A (es) | 2014-03-24 | 2015-03-24 | Aptamero para el factor de crecimiento de fibroblastos 2 y uso del mismo. |
Country Status (18)
Country | Link |
---|---|
US (1) | US9987298B2 (es) |
EP (1) | EP3124611B1 (es) |
JP (1) | JP6634554B2 (es) |
KR (1) | KR102394676B1 (es) |
CN (1) | CN106103719B (es) |
AU (1) | AU2015235020B2 (es) |
BR (1) | BR112016020984A2 (es) |
CA (1) | CA2943772C (es) |
DK (1) | DK3124611T3 (es) |
ES (1) | ES2768693T3 (es) |
HU (1) | HUE048529T2 (es) |
IL (1) | IL247998B (es) |
MX (1) | MX2016012466A (es) |
PL (1) | PL3124611T3 (es) |
PT (1) | PT3124611T (es) |
RU (1) | RU2686992C2 (es) |
SG (1) | SG11201607906RA (es) |
WO (1) | WO2015147017A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3105002A1 (en) | 2018-06-29 | 2020-01-02 | Ribomic Inc. | Aptamer preparation |
CN114853869B (zh) * | 2019-12-10 | 2023-12-26 | 湖南赛奥维生物技术有限公司 | 一种碱性成纤维细胞生长因子替代物及其组合物和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6177557B1 (en) * | 1990-06-11 | 2001-01-23 | Nexstar Pharmaceuticals, Inc. | High affinity ligands of basic fibroblast growth factor and thrombin |
KR970002255B1 (ko) | 1990-06-11 | 1997-02-26 | 넥스스타 파아마슈티컬드, 인크. | 핵산 리간드 |
PT668931E (pt) | 1992-09-29 | 2006-05-31 | Gilead Sciences Inc | Ligandos de acidos nucleicos e metodos para producao dos mesmos |
ATE518965T1 (de) * | 1992-09-29 | 2011-08-15 | Gilead Sciences Inc | Nukleinsäureliganden und ihre herstellungsmethoden |
EP0724647A4 (en) | 1993-09-08 | 2003-09-17 | Gilead Sciences Inc | NUCLEIC ACIDS AS LIGANDS AND IMPROVED PRODUCTION METHODS |
US7795419B2 (en) * | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
RU2410432C1 (ru) * | 2009-11-23 | 2011-01-27 | Государственное учреждение Научно-исследовательский институт физико-химической биологии имени А.Н. Белозерского Московского государственного университета имени М.В. Ломоносова | Модифицированные днк аптамеры, ингибирующие активность тромбина |
US8772259B2 (en) * | 2010-02-12 | 2014-07-08 | Ribomic Inc. | Aptamer to FGF2 and use thereof |
EP3345915B1 (en) * | 2010-04-12 | 2021-11-24 | Somalogic, Inc. | 5-position modified pyrimidines and their use |
WO2013186857A1 (ja) * | 2012-06-12 | 2013-12-19 | 株式会社リボミック | Fgf2に対するアプタマー及びその使用 |
-
2015
- 2015-03-24 CN CN201580015642.1A patent/CN106103719B/zh active Active
- 2015-03-24 HU HUE15767725A patent/HUE048529T2/hu unknown
- 2015-03-24 PT PT157677253T patent/PT3124611T/pt unknown
- 2015-03-24 PL PL15767725T patent/PL3124611T3/pl unknown
- 2015-03-24 US US15/128,495 patent/US9987298B2/en active Active
- 2015-03-24 RU RU2016141263A patent/RU2686992C2/ru active
- 2015-03-24 ES ES15767725T patent/ES2768693T3/es active Active
- 2015-03-24 JP JP2016510402A patent/JP6634554B2/ja active Active
- 2015-03-24 MX MX2016012466A patent/MX2016012466A/es active IP Right Grant
- 2015-03-24 BR BR112016020984A patent/BR112016020984A2/pt not_active IP Right Cessation
- 2015-03-24 KR KR1020167029463A patent/KR102394676B1/ko active IP Right Grant
- 2015-03-24 SG SG11201607906RA patent/SG11201607906RA/en unknown
- 2015-03-24 DK DK15767725.3T patent/DK3124611T3/da active
- 2015-03-24 WO PCT/JP2015/058992 patent/WO2015147017A1/ja active Application Filing
- 2015-03-24 EP EP15767725.3A patent/EP3124611B1/en active Active
- 2015-03-24 CA CA2943772A patent/CA2943772C/en active Active
- 2015-03-24 AU AU2015235020A patent/AU2015235020B2/en active Active
-
2016
- 2016-09-22 IL IL247998A patent/IL247998B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
RU2016141263A (ru) | 2018-04-26 |
CN106103719B (zh) | 2019-12-13 |
EP3124611A4 (en) | 2017-10-25 |
EP3124611A1 (en) | 2017-02-01 |
KR102394676B1 (ko) | 2022-05-09 |
PT3124611T (pt) | 2020-02-17 |
RU2016141263A3 (es) | 2018-10-12 |
EP3124611B1 (en) | 2019-11-06 |
PL3124611T3 (pl) | 2020-05-18 |
CA2943772A1 (en) | 2015-10-01 |
AU2015235020A1 (en) | 2016-11-10 |
CA2943772C (en) | 2022-07-19 |
JPWO2015147017A1 (ja) | 2017-04-13 |
IL247998A0 (en) | 2016-11-30 |
RU2686992C2 (ru) | 2019-05-06 |
JP6634554B2 (ja) | 2020-01-22 |
AU2015235020B2 (en) | 2020-10-22 |
IL247998B (en) | 2020-09-30 |
ES2768693T3 (es) | 2020-06-23 |
US20170157165A1 (en) | 2017-06-08 |
KR20160135819A (ko) | 2016-11-28 |
SG11201607906RA (en) | 2016-11-29 |
BR112016020984A2 (pt) | 2017-10-03 |
HUE048529T2 (hu) | 2020-07-28 |
CN106103719A (zh) | 2016-11-09 |
US9987298B2 (en) | 2018-06-05 |
DK3124611T3 (da) | 2020-01-27 |
WO2015147017A1 (ja) | 2015-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3675714A4 (en) | DEVICES AND METHODS FOR VASCULAR NAVIGATION, EVALUATION AND / OR DIAGNOSIS | |
EP3518806A4 (en) | METHODS AND DEVICES FOR DIAGNOSIS AND / OR DELIVERY OF ARRHYTHMIA TREATMENT, AND ROBOTIC SYSTEMS FOR OTHER PURPOSES | |
EP3675932A4 (en) | SYSTEMS, METHODS, APPARATUS AND DEVICES FOR THE ADMINISTRATION OF THE MEDICINAL PRODUCT OR SUBSTANCE | |
MX2018008190A (es) | Sistemas y metodos para la administracion transdermica a largo plazo. | |
MX2017003478A (es) | Anticuerpos anti-fgfr2/3 y metodos para su uso. | |
MX2016015511A (es) | Compuestos que comprenden grupo auto-destructivo. | |
EP3150202A4 (en) | Drug carrier for tumour-specific targeted drug delivery and use thereof | |
EP3660040A3 (en) | Insulin receptor partial agonists | |
EP3451908A4 (en) | DEVICES FOR NAVIGATION, EVALUATION AND / OR VASCULAR DIAGNOSIS. | |
EP3411330A4 (en) | CARBON QUANTITATIVE POINTS FOR DIAGNOSTIC ANALYSIS AND DRUG RELIEF | |
WO2015179548A3 (en) | Insert for catheter system | |
EP3398567A4 (en) | INTERVENTIONAL MEDICAL INSTRUMENT, INVESTMENT APPARATUS AND INTERVENTIONAL MEDICAL SYSTEM | |
EP3452147A4 (en) | DEVICES, METHODS AND SYSTEMS FOR THE ADMINISTRATION OF MEDICINES WITH MEDICINE KITS | |
EP3318282A4 (en) | DRUG DELIVERY VECTOR, AND COMPOSITION CONTAINING THE SAME | |
EP3415141A4 (en) | ULTRAVIOLET-CURING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL DELIVERY, AND CATAPLASM AGENT COMPRISING THE SAME | |
EP3525744A4 (en) | METHODS, SYSTEMS AND COMPUTER READABLE MEDIA FOR ASSESSING RISKS ASSOCIATED WITH VASCULAR PATHOLOGIES | |
WO2018115432A3 (en) | COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE | |
EP3545916A4 (en) | MEDICAL INTERVENTION INSTRUMENT DELIVERY SYSTEM | |
EP3395385A4 (en) | DRUG INFUSION DEVICE, CARTRIDGE ADAPTER, AND DRUG INFUSION SYSTEM | |
EP3431595A4 (en) | MONITORING AND DIAGNOSIS FOR IMMUNOTHERAPY AND DESIGN FOR THERAPEUTICS | |
MX2016011938A (es) | Composicion farmaceutica liquida. | |
EP3373977A4 (en) | CELLULAR PENETRATION-RICH GUANIDINIC OLIGOPHOSPHOTRIESTERS FOR THE DELIVERY OF MEDICATION AND PROBE | |
EP3449963A4 (en) | SYRINGE CYLINDER FOR PRE-FILLED SYRINGE, SYRINGE SYSTEM, AND PRE-FILLED SYRINGE | |
MX2022006154A (es) | Combinaciones y sus usos. | |
WO2016133449A9 (en) | Detection and treatment of malignant tumours in the cns |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |